Literature DB >> 1645748

Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells.

M Kohno1, K Yasunari, K Yokokawa, K Murakawa, T Horio, T Takeda.   

Abstract

We examined the inhibition by atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) of endothelin-1 secretion stimulated by angiotensin II (ANGII) and thrombin using cultured human umbilical-vein endothelial cells. ANGII and thrombin dose-dependently stimulated immunoreactive (ir) endothelin-1 secretion. Human ANP(1-28) and human BNP-32 both inhibited such secretion in a dose-dependent way. Inhibition of this secretion by ANP and BNP was paralleled by an increase in the level of cyclic guanosine 5'-monophosphate (GMP). The addition of a cyclic GMP analogue, 8-bromo cyclic GMP, reduced this stimulated secretion. Rat ANP(5-25) was weaker than human ANP(1-28) at inhibiting ir-endothelin-1 secretion and increasing cyclic GMP in the cells. ir-Endothelin-1 in the medium consisted of two components separated by high pressure liquid chromatography; the major one corresponded to endothelin-1(1-21) and the minor one corresponded to big endothelin-1(1-38). Treatment with ANP and BNP did not affect this profile. These findings suggest that human ANP and BNP inhibit endothelin-1 secretion stimulated by ANGII and thrombin in these cells through a cyclic GMP-dependent process. Taken together with endothelin stimulation of ANP and BNP secretion from the heart, our results suggest the existence of a cardiac-endothelium feedback.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645748      PMCID: PMC296954          DOI: 10.1172/JCI115228

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Circulating immunoreactive endothelin in ischemic heart disease.

Authors:  M Yasuda; M Kohno; A Tahara; H Itagane; I Toda; K Akioka; M Teragaki; H Oku; K Takeuchi; T Takeda
Journal:  Am Heart J       Date:  1990-04       Impact factor: 4.749

2.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

3.  Circulating atrial natriuretic peptides during exercise in patients with chronic respiratory failure.

Authors:  M Kohno; K Murakawa; N Kurihara; T Takeda; Y Araki; H Matusita
Journal:  Chest       Date:  1987-10       Impact factor: 9.410

4.  Effect of exercise on circulating atrial natriuretic polypeptide in valvular heart disease.

Authors:  T Nishikimi; M Kohno; T Matsuura; K Akioka; M Teragaki; M Yasuda; H Oku; K Takeuchi; T Takeda
Journal:  Am J Cardiol       Date:  1986-11-15       Impact factor: 2.778

5.  Alpha-human atrial natriuretic polypeptide is released from the heart and circulates in the body.

Authors:  A Sugawara; K Nakao; N Morii; M Sakamoto; M Suda; M Shimokura; Y Kiso; M Kihara; Y Yamori; K Nishimura
Journal:  Biochem Biophys Res Commun       Date:  1985-06-14       Impact factor: 3.575

6.  Radioimmunoassay of atrial natriuretic factor: human plasma levels.

Authors:  P Larose; S Meloche; P du Souich; A Deléan; H Ong
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

7.  Atrial natriuretic peptide elevation in congestive heart failure in the human.

Authors:  J C Burnett; P C Kao; D C Hu; D W Heser; D Heublein; J P Granger; T J Opgenorth; G S Reeder
Journal:  Science       Date:  1986-03-07       Impact factor: 47.728

8.  Atrial natriuretic factor--a circulating hormone stimulated by volume loading.

Authors:  R E Lang; H Thölken; D Ganten; F C Luft; H Ruskoaho; T Unger
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

9.  Effects of volume change on circulating immunoreactive atrial natriuretic factor in rats.

Authors:  M Kohno; K B Clegg; M P Sambhi
Journal:  Hypertension       Date:  1987-08       Impact factor: 10.190

10.  Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes.

Authors:  Y Fukuda; Y Hirata; H Yoshimi; T Kojima; Y Kobayashi; M Yanagisawa; T Masaki
Journal:  Biochem Biophys Res Commun       Date:  1988-08-30       Impact factor: 3.575

View more
  10 in total

Review 1.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

3.  Differential localization of endothelin ETA and ETB binding sites in human placenta.

Authors:  R A Rutherford; J Wharton; A McCarthy; L Gordon; M H Sullivan; M G Elder; J M Polak
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

4.  Regulatable atrial natriuretic peptide gene therapy for hypertension.

Authors:  Kurt J Schillinger; Sophia Y Tsai; George E Taffet; Anilkumar K Reddy; Ali J Marian; Mark L Entman; Kazuhiro Oka; Lawrence Chan; Bert W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-14       Impact factor: 11.205

5.  Endogenous cardiac vasoactive factors modulate endothelin production by cardiac fibroblasts in culture.

Authors:  K L King; J Winer; J P Mather
Journal:  Endocrine       Date:  1996-08       Impact factor: 3.633

Review 6.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

7.  Clinical significance of plasma endothelin-1 in patients with chronic liver disease.

Authors:  H Matsumoto; J Uemasu; M Kitano; H Kawasaki
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

8.  Natriuretic Peptide Receptor-C is Up-Regulated in the Intima of Advanced Carotid Artery Atherosclerosis.

Authors:  Mohamed A Zayed; Scott D Harring; Dana R Abendschein; Chandu Vemuri; Dongsi Lu; Lisa Detering; Yongjian Liu; Pamela K Woodard
Journal:  J Med Surg Pathol       Date:  2016-07-05

Review 9.  Eyeing endothelins: a cellular perspective.

Authors:  Ganesh Prasanna; Santosh Narayan; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

10.  Regional haemodynamic effects of antagonists of angiotensin II, endothelin and adrenoceptors in conscious, vasopressin-deficient, genetically hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.